Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 16, 2013, under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 665,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,659.00 pence; lowest price paid was 1,643.50 pence.
- Treasury Holdings (Settled): 509,460,412 shares (9.41% of total issued share capital).
- Treasury Holdings (Including Unsettled): 511,234,412 shares (10.43% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,903,515,672 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 665,000 shares on August 16, 2013. Consequently, the percentage of total voting rights held in Treasury increased to 10.43% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,460,412 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.43% held in Treasury including unsettled shares).
- Check the number of shares in issue (4,903,515,672) to ensure accurate denominator usage for disclosure thresholds under FCA rules.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial metrics.